drugset / Trial / NCT00265200
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
Phase 2
Terminated
28 enrolled
University of Louisville
James Graham Brown Cancer Center · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.
Timeline
- Start
- 2005-02
- Primary completion
- 2009-08
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zoledronic acid | Other / unclassified | 3 mg | Intravenous |
| Subject | Zoledronic acid | Other / unclassified | 4 mg | Intravenous |